Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

Name: Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS
Published: 2008
License: Public Domain

Sunnybrook Health Sciences Centre · 2008

ClinicalTrials.gov · Datasets · License: Public Domain · 2008

Open Source ↗

angiogenesis chronic leukemia

myelodysplastic syndromes, leukemia, myelomonocytic, chronic, angiogenesis, myelodysplastic syndrome, chronic myelomonocytic leukemia, high intermediate risk and high risk ipss score, metronomic chemotherapy, myelodysplastic myeloproliferative diseases, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

Related documents